Anticytokine autoantibody-Associated immunodeficiency

Annual Review of Immunology

Volumn 32, Issue , 2014, Pages 635-657

  Browne, Sarah K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anticytokine autoantibodies; GM CSF; Granulocyte macrophage colony stimulating factor; IFN ; IL 17; Immunodeficiency; Interferon gamma; Interleukin 17

Indexed keywords

NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; CELL TYPE; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; AUTOANTIBODIES; CANDIDIASIS; CYTOKINES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; POLYENDOCRINOPATHIES, AUTOIMMUNE; THYMOMA;

EID: 84897106065     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032713-120222     Document Type: Review

References (151)

1. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, et al. 2012. Adultonset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367:725-34
2. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, et al. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-Associated cytokines. J. Exp. Med. 207:299-308
3. Puel A, Doffinger R, Natividad A, ChrabiehM, Barcenas-Morales G, et al. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207:291-97
4. Carey B, Trapnell BC. 2010. The molecular basis of pulmonary alveolar proteinosis. Clin. Immunol. 135:223-35
5. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, et al. 2013. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190:3959-66
6. Watanabe M, Uchida K, Nakagaki K, Kanazawa H, Trapnell BC, et al. 2007. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581:2017-21
7. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, et al. 2009. Granulocyte/macrophage-colonystimulating factor autoantibodies andmyeloid cell immune functions in healthy subjects. Blood 113:2547-56
8. Bost KL,Hahn BH, Saag MS, ShawGM, Weigent DA, et al. 1988. Individuals infected with HIV possess antibodies against IL-2. Immunology 65:611-15
9. Madariaga L, Amurrio C, Martin G, Garcia-Cebrian F, Bicandi J, et al. 1998. Detection of antiinterferon- γ autoantibodies in subjects infected by Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2:62-68
10. Bonfanti C, Caruso A, Bakhiet M, Olsson T, Turano A, et al. 1995. Increased levels of antibodies to IFN-γin human and experimental African trypanosomiasis. Scand. J. Immunol. 41:49-52
11. PrummerO, BunjesD,WiesnethM,ArnoldR, Porzsolt F, et al. 1994. High-titre interferon-αantibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 14:483-86
12. PrummerO, FrickhofenN,DigelW,HeimpelH, Porzsolt F. 1991. Spontaneous interferon-αantibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann. Hematol. 62:76-80
13. Fomsgaard A, SvensonM, Bendtzen K. 1989. Auto-Antibodies to tumour necrosis factorαin healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand. J. Immunol. 30:219-23
14. Wildbaum G, Nahir MA, Karin N. 2003. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19:679-88
15. Peichl P, Pursch E, Broll H, Lindley IJ. 1999. Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol. Int. 18:141-45
16. Lokshin AE,WinansM, Landsittel D,Marrangoni AM, Velikokhatnaya L, et al. 2006. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol. 102:244-51
17. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, et al. 1996. Presence of autoantibodies to interleukin-8 or neutrophil-Activating peptide-2 in patients with heparin-Associated thrombocytopenia. Blood 88:410-16
18. Kurdowska A, Miller EJ, Noble JM, Baughman RP, Matthay MA, et al. 1996. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J. Immunol. 157:2699-706
19. Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, et al. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin. Exp. Immunol. 104:384-87
20. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, et al. 1998. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J. Interferon Cytokine Res. 18:345-50
21. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, et al. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-75
22. Armitage JO. 1998. Emerging applications of recombinant human granulocyte-macrophage colonystimulating factor. Blood 92:4491-508
23. Akagawa KS, Kamoshita K, Tokunaga T. 1988. Effects of granulocyte-macrophage colony-stimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages. J. Immunol. 141:3383-90
24. Bonfield TL, Raychaudhuri B,Malur A, Abraham S, Trapnell BC, et al. 2003. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am. J. Physiol. Lung Cell. Mol. Physiol. 285:L1132-36
25. Chen BD, Mueller M, Chou TH. 1988. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J. Immunol. 141:139-44
26. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M,Whitsett JA, et al. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557-67
27. Rosen SH, Castleman B,Liebow AA. 1958. Pulmonary alveolar proteinosis. N. Engl. J.Med. 258:1123-42
28. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, et al. 1994. Involvement of granulocytemacrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713-16
29. Robb L, Drinkwater CC, Metcalf D, Li R, Kontgen F, et al. 1995. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc. Natl. Acad. Sci. USA 92:9565-69
30. DirksenU,Nishinakamura R, Groneck P,HattenhorstU,Nogee L, et al. 1997. Human pulmonary alveolar proteinosis associated with a defect inGM-CSF/IL-3/IL-5 receptor common beta chain expression. J. Clin. Investig. 100:2211-17
31. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, et al. 2008. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J. Exp. Med. 205:2703-10
32. Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, et al. 2010. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy.Am. J. Respir. Crit. CareMed. 182:1292-304
33. Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, et al. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190:875-80
34. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, et al. 1999. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 442:246-50
35. Seymour JF, Presneill JJ. 2002. Pulmonary alveolar proteinosis: progress in the first 44 years. Am. J. Respir. Crit. Care Med. 166:215-35
36. Ladeb S, Fleury-Feith J, Escudier E, Tran Van Nhieu J, Bernaudin JF, et al. 1996. Secondary alveolar proteinosis in cancer patients. Support. Care Cancer 4:420-26
37. Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, et al. 2011. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118:2653-55
38. YoshidaM, Ikegami M, Reed JA, Chroneos ZC,Whitsett JA. 2001. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L379-86
39. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, et al. 2007. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N. Engl. J. Med. 356:567-79
40. Fried J, Hinthorn D, Ralstin J, Gerjarusak P, Liu C. 1988. Cure of brain abscess caused by Nocardia asteroides resistant to multiple antibiotics. South. Med. J. 81:412-13
41. Walker DA, McMahon SM. 1986. Pulmonary alveolar proteinosis complicated by cerebral abscess: report of a case. J. Am. Osteopath. Assoc. 86:447-50
42. Ramirez J. 1967. Pulmonary alveolar proteinosis. Treatment bymassive bronchopulmonary lavage. Arch. Intern. Med. 119:147-56
43. Witty LA, Tapson VF, Piantadosi CA. 1994. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine 73:103-9
44. HartungM, Salfelder K. 1975. Pulmonary alveolar proteinosis and histoplasmosis: report of three cases. Virchows Arch. A Pathol. Anat. Histol. 368:281-87
45. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, et al. 2000. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am. J. Respir. Crit. CareMed. 162:658-62
46. Carlsen ET, Hill RB Jr, Rowlands DT Jr. 1964. Nocardiosis and pulmonary alveolar proteinosis. Ann. Intern. Med. 60:275-81
47. OerlemansWG, Jansen EN, Prevo RL, Eijsvogel MM. 1998. Primary cerebellar nocardiosis and alveolar proteinosis. Acta Neurol. Scand. 97:138-41
48. Saltzman HA, Chick EW, Conant NF. 1962. Nocardiosis as a complication of other diseases. Lab. Investig. 11:1110-17
49. Supena R, Karlin D, Strate R, Cramer PG. 1974. Pulmonary alveolar proteinosis and Nocardia brain abscess. Report of a case. Arch. Neurol. 30:266-68
50. Taleghani-Far M, Barber JB, Sampson C, Harden KA. 1964. Cerebral nocardiosis and alveolar proteinosis. Am. Rev. Respir. Dis. 89:561-65
51. Clague HW, Harth M, Hellyer D, Morgan WK. 1982. Septic arthritis due to Nocardia asteroides in association with pulmonary alveolar proteinosis. J. Rheumatol. 9:469-72
52. Andersen BR, Ecklund RE,KellowWF. 1960. Pulmonary alveolar proteinosis with systemic nocardiosis. A case report. JAMA 174:28-31
53. Andriole VT, Ballas M, Wilson GL. 1964. The association of nocardiosis and pulmonary alveolar proteinosis. A case study. Ann. Intern. Med. 60:266-75
54. Bjorkholm B, Elgefors B. 1986. Cerebellar aspergilloma. Scand. J. Infect. Dis. 18:375-8
55. Jones CC. 1960. Pulmonary alveolar proteinosis with unusual complicating infections; a report of two cases. Am. J. Med. 29:713-22
56. Wolman L. 1961. The cerebral complications of pulmonary alveolar proteinosis. Lancet 2:733-35
57. Kavuru MS, Sullivan EJ, Piccin R, ThomassenMJ, Stoller JK. 2000. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 161:1143-48
58. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, et al. 2001. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am. J. Respir. Crit. CareMed. 163:524-31
59. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, et al. 2010. Inhaled granulocyte/macrophagecolony stimulating factor as therapy for pulmonary alveolar proteinosis. Am. J. Respir. Crit. CareMed. 181:1345-54
60. BorieR,DebrayMP, LaineC,Aubier M, Crestani B. 2009. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur. Respir. J. 33:1503-6
61. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, et al. 2011. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur. Respir. J. 38:1361-67
62. Dorman SE, Holland SM. 2000. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11:321-33
63. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, et al. 2011. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365:127-38
64. Bogunovic D, Byun M, Durfee LA,Abhyankar A, SanalO, et al. 2012. Mycobacterial disease and impaired IFN-γimmunity in humans with inherited ISG15 deficiency. Science 337:1684-88
65. Al-Muhsen S,Casanova JL. 2008.The genetic heterogeneity ofMendelian susceptibility tomycobacterial diseases. J. Allergy Clin. Immunol. 122:1043-51
66. Doffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, et al. 2004. Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38:e10-14
67. Hoflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, et al. 2004. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103:673-75
68. Baerlecken N, Jacobs R, Stoll M, Schmidt RE, Witte T. 2009. Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-γautoantibody. Clin. Infect. Dis. 49:e76-78
69. Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, et al. 2012. Anti-CD20 (rituximab) therapy for anti-interferon-γ autoantibody- Associated nontuberculous mycobacterial infection. Blood 119:3933-39
70. Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, et al. 2012. Anti-interferon- γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1?16:02 and DQB1?05:02 and the reactivation of latent varicella-zoster virus infection. Blood 121:1357-66
71. Kampitak T, Suwanpimolkul G, Browne S, Suankratay C. 2010. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature. Infection 39:65-71
72. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, et al. 2005. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J. Clin. Investig. 115:2480-88
73. Koya T, Tsubata C, Kagamu H, Koyama K, Hayashi M, et al. 2009. Anti-interferon-γautoantibody in a patient with disseminated Mycobacterium avium complex. J. Infect. Chemother. 15:118-22
74. Patel SY, Ding L, Brown MR, Lantz L, Gay T, et al. 2005. Anti-IFN-γautoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175:4769-76
75. Poulin S, Corbeil C, Nguyen M, St-Denis A, Cote L, et al. 2013. Fatal Mycobacterium colombiense/ cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. BMC Infect. Dis. 13:24
76. Tanaka Y, Hori T, Ito K, Fujita T, Ishikawa T, et al. 2007. Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-γ. Intern. Med. 46:1005-9
77. Tang BS, Chan JF, Chen M, Tsang OT, Mok MY, et al. 2010. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. Clin. Vaccine Immunol. 17:1132-38
78. Xu S, Cao X. 2010. Interleukin-17 and its expanding biological functions. Cell Mol. Immunol. 7:164-74
79. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, et al. 2008. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 205:1543-50
80. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, et al. 2008. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-76
81. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, et al. 2009. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361:1760-67
82. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727-35
83. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, et al. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65-68
84. Aaltonen J, Bj orses P, Perheentupa J, Horelli-Kuitunen N, Palotie A, et al. 1997. An autoimmune disease, APECED, caused bymutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17:399-403
85. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, et al. 2002. Projection of an immunological self shadow within the thymus by the Aire protein. Science 298:1395-401
86. Scarpino S, Di Napoli A, Stoppacciaro A, Antonelli M, Pilozzi E, et al. 2007. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 149:504-12
87. Strobel P,Murumagi A,Klein R, LusterM, Lahti M, et al. 2007. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 211:563-71
88. Tarr PE, Sneller MC, Mechanic LJ, Economides A, Eger CM, et al. 2001. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine 80:123-33
89. Jones SA. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175:3463-68
90. Galle P, SvensonM, Bendtzen K, HansenMB. 2004. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur. J. Immunol. 34:3267-75
91. Hansen MB, SvensonM,DiamantM, BendtzenK. 1991. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33:777-81
92. Homann C, Hansen MB, Graudal N, Hasselqvist P, Svenson M, et al. 1996. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. Scand. J. Immunol. 44:623-29
93. Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, et al. 2013. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann. Rheum. Dis. 72:1100-2
94. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, et al. 2008. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180:647-54
95. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-19
96. Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, et al. 1989. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 73:117-22
97. Roberts AW. 2005. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 23:33-41
98. Eyles JL, Roberts AW, Metcalf D, Wicks IP. 2006. Granulocyte colony-stimulating factor and neutrophils: forgotten mediators of inflammatory disease. Nat. Clin. Pract. Rheumatol. 2:500-10
99. Laricchia-Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. 1997. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J. Cell. Physiol. 173:219-26
100. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. 2002. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum. 46:2384-91
101. Campion G, Maddison PJ, Goulding N, James I, Ahern MJ, et al. 1990. The Felty syndrome: a casematched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine 69:69-80
102. Ruderman M, Miller LM, Pinals RS. 1968. Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum. 11:377-84
103. Cappellano G, Orilieri E, Woldetsadik AD, Boggio E, Soluri MF, et al. 2012. Anti-cytokine autoantibodies in autoimmune diseases. Am. J. Clin. Exp. Immunol. 1:136-46
104. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, et al. 1996. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93:14002-7
105. Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, et al. 2013. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine 92:109-22
106. van de Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, et al. 2013. IL-12Rβ1 deficiency: mutation update and description of the IL12RB1 variation database. Hum. Mutat. 34:1329-39
107. Sim BT, Browne SK, Vigliani M, Zachary D, Rosen L, et al. 2013. Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies. J. Clin. Immunol. 33:1057-61
108. Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, et al. 2010. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 116:4848-58
109. SzaboG,Dolganiuc A. 2008. The role of plasmacytoid dendritic cell-derivedIFNαin antiviral immunity. Crit. Rev. Immunol. 28:61-94
110. Ross C, Hansen MB, Schyberg T, Berg K. 1990. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-α2b and human IFN-γ in healthy blood donors. Clin. Exp. Immunol. 82:57-62
111. Prummer O, Seyfarth C, Scherbaum WA, Drees N, Porzsolt F. 1989. Interferon-α antibodies in autoimmune diseases. J. Interferon Res. 9(Suppl. 1):S67-74
112. Trown PW, Kramer MJ, Dennin RA Jr, Connell EV, Palleroni AV, et al. 1983. Antibodies to human leucocyte interferons in cancer patients. Lancet 1:81-84
113. Bagnato F, Clemenzi A, Scagnolari C, Strizzi L, Di Pasquale A, et al. 2004. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. Eur. Cytokine Netw. 15:24-29
114. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, et al. 2003. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-α, interferon-? and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132:128-36
115. ShionoH,Wong YL, Matthews I, Liu JL, Zhang W, et al. 2003. Spontaneous production of anti-IFN-α and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15:903-13
116. Meager A, Visvalingam K, Peterson P,Moll K,Murumagi A, et al. 2006. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3:e289
117. Pozzetto B, Mogensen KE, Tovey MG, Gresser I. 1984. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J. Infect. Dis. 150:707-13
118. Kisand K, Link M, Wolff AS, Meager A, Tserel L, et al. 2008. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 112:2657-66
119. Panem S, Check IJ, Henriksen D, Vilcek J. 1982. Antibodies to α-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129:1-3
120. Suit BE, Axelrod D, Moutsopoulos HM, Decker JL, Hooks JJ. 1983. Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin. Exp. Rheumatol. 1:133-5
121. Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, et al. 2011. Association of endogenous anti-interferon-αautoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 63:2407-15
122. Slavikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, et al. 2003. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J. Interferon Cytokine Res. 23:143-47
123. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-15
124. Bjorses P,HalonenM, Palvimo JJ, Kolmer M, Aaltonen J, et al. 2000. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasisectodermal dystrophy protein. Am. J. Hum. Genet. 66:378-92
125. Derbinski J, Schulte A, Kyewski B, Klein L. 2001. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2:1032-39
126. Kisand K, Peterson P. 2011. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann. NY Acad. Sci. 1246:77-91
127. Perheentupa J. 2002. APS-I/APECED: the clinical disease and therapy. Endocrinol. Metab. Clin. North Am. 31:295-320
128. Nagafuchi S, Umene K, Yamanaka F, Oohashi S, ShindoM, et al. 2007. Recurrent herpes simplex virus infection in a patientwith autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1GC compound heterozygous autoimmune regulator gene mutations. J. Intern. Med. 261:605-10
129. Proust-Lemoine E, Saugier-Veber P, Lefranc D, Dubucquoi S, Ryndak A, et al. 2010. Autoimmune polyendocrine syndrome type 1 in north-western France: AIRE gene mutation specificities and severe forms needing immunosuppressive therapies. Horm. Res. Paediatr. 74:275-84
130. KhawajaMR, Nelson RP Jr,Miller N, Badve SS, Loehrer E, et al. 2012. Immune-mediated diseases and immunodeficiencies associated with thymic epithelial neoplasms. J. Clin. Immunol. 32:430-37
131. Vincent A, Willcox N. 1999. The role of T-cells in the initiation of autoantibody responses in thymoma patients. Pathol. Res. Pract. 195:535-40
132. Meager A, Vincent A, Newsom-Davis J, Willcox N. 1997. Spontaneous neutralising antibodies to interferon-αand interleukin-12 in thymoma-Associated autoimmune disease. Lancet 350:1596-97
133. Offerhaus GJ, Schipper ME, Lazenby AJ, Montgomery E, Morsink FH, et al. 2007. Graft-versus-hostlike disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? Immunol. Lett. 114:31-37
134. Kelleher P,Misbah SA. 2003. What is Good's syndrome? Immunological abnormalities in patients with thymoma. J. Clin. Pathol. 56:12-16
135. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311:1924-27
136. Courtney LP, Phelps JL, Karavodin LM. 1994. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology 28:223-32
137. Zhang L, Barker JM, Babu S, Su M, StenersonM, et al. 2007. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125:131-37
138. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, et al. 2011. Determination of human anticytokine autoantibody profiles using a particle-based approach. J. Clin. Immunol. 32:238-45
139. Uchida K, Carey B, Suzuki T,Nakata K, Trapnell B. 2010. Response:Granulocyte/macrophage colonystimulating factor autoantibodies and myeloid cell immune functions in healthy persons. Blood 115:431-33
140. Schoch OD, Schanz U, Koller M, Nakata K, Seymour JF, et al. 2002. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 57:277-80
141. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, et al. 2008. Sustained response to rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J. Neuroimmunol. 201-2:90-94
142. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. 2006. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355:1772-79
143. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, et al. 2009. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med. 361:1848-55
144. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, et al. 1996. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N. Engl. J. Med. 334:630-33
145. Riches PL, McRorie E, Fraser WD, Determann C, van't Hof R, et al. 2009. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N. Engl. J. Med. 361:1459-65
146. Browne SK, Holland SM. 2010. Anti-cytokine autoantibodies explain some chronic mucocutaneous candidiasis. Immunol. Cell Biol. 88:614-15
147. Kirkness EF, Venter JC. 1989. Anti-receptor antibodies. Curr. Opin. Immunol. 1:679-83
148. Martinez-MoczygembaM,DoanML, Elidemir O, Fan LL, Cheung SW, et al. 2008. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRαgene in the X chromosome pseudoautosomal region J. Exp. Med. 205:2711-16
149. Chen GH, Curtis JL, Mody CH, Christensen PJ, Armstrong LR, et al. 1994. Effect of granulocytemacrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J. Immunol. 152:724-34
150. Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, et al. 2010. Patient-derived granulocyte/ macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am. J. Respir. Crit. CareMed. 182:49-61
151. Aujla SJ, Kolls JK. 2009. IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 87:451-54